Totally disagree on this one Erick. This pandemic is killing a ton of people and the need for a rapid, accurate, inexpensive test is paramount. Priorities shift through time and a COVID test should take priority over the N-Assay test development for GBS. With the patent we have the "potential", which NNLX likes to use extensively, to help bring this pandemic under control and the company should put priority on the COVID test development and getting it to market. Apparently they are working on it but the track record of this company getting anything to market is dismal. The test product apparently works, this the patent approval. Shouldn't take that long IMO to get a partner and the product to market.